English · Not set Change ▾

Live scores ticker: On · Turn off

Markets ticker: On · Turn off

Saved in a cookie on this device (and in your account when you are logged in). We never store your IP address.

Entities › name

Neck Cancer

3 headlines · 2 outlets · 2026-11-02 → 2026-11-06 · Wikipedia ↗ · 🔒 Follow

Latest coverage

PR Newswire: Health ·Nov 6, 2026

Press releases
Country: United States

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug...

Health Markets Details Archived copy ↗

PR Newswire: Health ·Nov 6, 2026

Press releases
Country: United States

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a...

Health Details Archived copy ↗

Neck Cancer

Latest coverage

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

Explore

News

Daily

Banana Watch & guides

Watch & listen

Sports

Local & weather

Understand & explore

Join

Banana News

Upgrade to unlock this

Keyboard shortcuts

Move

Go

Everywhere

Ask Ara